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1. Introduction  
Malignant melanoma can be currently allocated within the list of the most serious diseases 
with high mortality, every year, over 50,000 patients with this diagnosis die worldwide (Pirard 
& Vries, 2007). In addition, its incidence (200,000 per year worldwide) (Mathers et al., 2001) is 
still increasing due to deteriorating environmental factors (increased exposure to UV light, 
unhealthy lifestyle, pollution etc.). Chemotherapy is one of the most important therapeutic 
modalities of this diagnosis however, despite significant advances in the field of contemporary 
medicine and a broad portfolio of medicaments in use, the treatment success rate is still 
insufficient. For these reasons, scientific and pharmaceutical communities have intensively 
investigated new compounds that could be applied as new drugs for this devastating disease. 
Triterpenes - substances abundant in natural sources belong to a group of isoprenoids, 
compounds made of 6 isoprene building units. They have a wide spectrum of 
pharmacological activities (Dzubak et al., 2006), of which the most noteworthy are: antiviral, 
anti-inflammatory, antiulcerogenic, antimicrobial, anticariogenic and most importantly 
anticancer activity. Betulinic acid (1) and many other triterpenes have been known over a 
century, however, until recently their selective cytotoxic activity against human melanoma 
cells was undiscovered (Cichewicz & Kouzi, 2004; Eiznhamer & Xu, 2004; Salvador, 2010). 
The extract of Vauquelinia corymbosa (Fig. 1) showed significant cytotoxic activity against a 
cell line of lymphocytic leukemia P-388 in the work of Trumbull by 1976 and betulinic acid 
(1) along with uvaol and ursolic acid were supposed to be responsible for it (Trumbull et al., 
1976). Despite that, the fundamental study of selective cytotoxic activity of acid 1 against 
human melanoma cells MEL-1 with IC50 values in the range between 0.5 - 1.5 µg/mL was 
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reported by Pisha and his team (Pisha et al., 1995) incredible 19 years after Trumbull's paper. 
A large number of natural triterpenes have been isolated and many more semi-synthetic 
compounds have been prepared from them since then. Plenty of these derivatives also 
showed cytotoxic activity against melanoma cells (Salvador, 2010). 
In this chapter (Isolated pentacyclic triterpenes and Semi-synthetic triterpenoids), there 
will be a summary of representatives from both natural and semi-synthetic lupane 
triterpenoids with cytotoxic activity against melanoma cells that were studied during the 
past fifteen years. Current knowledge of the mechanisms of action of the leading 
representatives, results and aspects of in vivo tests and clinical trials will be discussed here. 
Betulinic acid (1) will be given the most attention as it is historically the first known 
triterpene with activity against melanoma. Betulinic acid (1) is currently in the second phase 
of clinical trials for treatment of dysplastic nevus and therefore, it has a high potential to be 
used in future clinical practice. 
 
 
Fig. 1. Vauquelinia corymbosa (Photo: Dr. Carlos Gerardo Velazco Macías) 
2. Anticancer effects of triterpenoids used for treatment of melanoma 
To date, several hundred triterpenoid compounds with significant in vitro cytotoxic activity 
against a variety of cancer cell lines have been found (Salvador, 2010) however; few of them 
were screened against human melanoma lines such as MEL-1, -2, -3, -4. Most of the 
triterpenes that actually were tested and showed interesting activity against melanoma cell 
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lines were derivatives of lupane. That is why this chapter will be focused on lupane 
triterpenoids with anti-melanoma activity and they will be divided into two groups 1) 
isolated pentacyclic triterpenoids, meaning they were isolated from a natural source and 2) 
semi-synthetic triterpenoids that were obtained by modification of natural compounds 
using chemical reactions or biotransformations. 
2.1 Isolated pentacyclic triterpenes 
Natural appearance and properties of betulinic acid (1) 
Betulinic acid (1) is a natural triterpene with extraordinarily high activity against human 
melanoma and is found throughout the plant kingdom (e.g. genus Betulla, Ziziphus, Syzigium, 
Diospiros, Paeonia) (Cichewicz & Kouzi, 2004). When isolated as a pure compound, this natural 
pentacyclic triterpene appears to be snow-white crystalline odorless and tasteless powder that 
is almost insoluble in water (Cichewicz & Kouzi, 2004; Glassby, 1982; Simonsen & Ross, 1957). 
 
 
Fig. 2. Gratiola officinalis (photo: http://botanika.wendys.cz); 
 
 
Fig. 3. Platanus acerifolia (photo: www.shutterstock.com); 
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Fig. 4. Ziziphus Mauritiana – bark (photo: http://en.wikipedia.org) 
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Fig. 5. 
The first isolation of the compound currently known as betulinic acid (1) was described by 
Retzlaff in 1902 (Retzlaff, 1902; Simonsen & Ross, 1957), who extracted the yet unknown 
substance from Gratiola officinalis (Fig. 2) which he called “graciolon”. In 1925, betulinic acid 
(1) was independently obtained from the bark of plane trees Platanus acerifolia (Fig. 3) by 
Zellner and Ziffer (Simonsen & Ross, 1957; Zellner & Ziffer, 1925) using either extraction or 
sublimation. The authors named it after its source “platanolic acid” and did not recognize its 
true identity. Similarly, the same compound was isolated from Florida Cornus (Fig. 6) during 
the dissertation research of Soliman who, in 1939 first called it “cornolic acid”. However, 
soon he and his co-workers identified it correctly as betulinic acid (1) (Robertson et al., 1939). 
In 1944, Barton and Jones used physical constants to correctly identify “graciolon” as 
betulinic acid (1) (Barton & Jones, 1944) and in 1948, Bruckner and co-workers identified 
(Bruckner et al., 1948) “platanolic acid” as betulinic acid (1) as well. Demonstrating, that 
betulinic acid (1) is widely spread throughout nature and that its identification was often 
accompanied with many problems during the 20th century. 
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Acid 1 is accessible from plane tree and birch bark on an industrial scale since both types of 
bark contain several percent of it. In addition to the extraction procedures (Cichewicz & 
Kouzi, 2004; Simonsen & Ross, 1957; Urban et al., 2004), several industrial processes were 
developed to manufacture (Csuk et al., 2006; Krasutsky et al., 2003, 2006; Pezzuto et al., 2007) 
betulinic acid (1) from betulin (3), a triterpene far more abundant (up to 30 %) in birch bark 
(e.g. Betula pendula; Fig. 7) than the acid, which makes it far more profitable process. This is 
especially useful in northern European countries, Russia, Canada, where paper mills mostly 
use birches to produce cellulose pulp and where over 40 tons of birch bark (Krasutsky, 2005, 
2006; Sarek, 2008) is produced daily, with 6 tons a day being burned as a cheap fuel (5-7 
USD per ton; 7-11 MJ/kg). Using birch bark as a cheap source of betulin can provide the 
industry with a less expensive source of betulinic acid (Csuk et al., 2006; Krasutsky, 2003, 
2006; Pezzuto, 2007). With these procedures, there should not be a significant problem with 
manufacturing betulinic acid (1) on a multi ton scale. The best known industrial process to 
convert betulin (3) into betulinic acid (1) is based on conversion of it into aldehyde 4 (Csuk 
et al., 2006; Krasutsky et al., 2006a, 2006b, 2006c) followed by oxidation (Csuk et al., 2006; 
Krasutsky et al., 2006) of aldehyde 4 to betulinic acid (1). Older patented procedures 
(Pezzuto et al., 2007) that use oxidation of betulin (3) with Jones reagent into betulonic acid 
(5) followed by selective reduction are not preferable because they use toxic Cr(VI) 
compounds in large quantities and also a 3-epimeric product originates as a by-product 
(Pezzuto, 2007) which makes the isolation and purification far too expensive. 
 
 
Fig. 6. Florida cornus – bark (photo: http://en.wikipedia.org); 
 
 
Fig. 7. Betula pendula (photo: www.shutterstock.com) 
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Antitumor activities of acid 1 against human melanoma cells 
Despite acid 1 having been isolated in 1902, its cytotoxic effects were not found until the 
examination of cytotoxicity of various Vaquelinia corymbosa (Fig. 1) extracts against 
lymphocytic leukemia cells P-388 by Trumbull in 1976 (Trumbull et al., 1976). Approximately 
19 years later, Pisha and his co-workers (Pisha et al., 1995) published their findings of selective 
cytotoxic effects of betulinic acid (1) extracted from stem bark of Ziziphus Mauritiana 
(Lamnaceae, Fig. 4) against human melanoma cells Mel-1, -2, -3, -4. Furthermore, this work 
investigated the mechanism of action by flow-cytometry (Pisha et al., 1995), and it was found 
that acid 1 induced selective apoptosis of tumor cells Mel-2, which remained in G0/G1 phase. 
Moreover, induction of apoptosis was evident from the emergence of sub-G1 apoptotic peak 
(Ap) in DNA histograms and its increase between 56-72 h after application. Direct 
perturbation of the mitochondria by betulinic acid (1) was observed by (Fulda et al., 1998) and 
this type of activity was also found when the cancer cells were treated by various triterpene 
scaffolds without limitation to the melanoma cells. Despite extensive research, the molecular 
target of betulinic acid (1) has not yet been identified. Only from some published pathway 
alterations like Bcl-2 and NF-kB modulation and antiangiogenic activity were some 
speculations about the target able to be made (Selzer et al., 2000, 2002). There is a plethora of 
information about the activity of potent derivatives of betulinic acid (1) (e.g. NVX-207, PA-457) 
in in vitro and in vivo models but it seems to be a reality, that small changes in the chemical 
structure could lead to significant differences in specificity and mechanisms of action (Keller et 
al., 2001; Suh et al., 1999; Willmann et al., 2009). 
Another advantage of using acid 1 in cancer therapy is its very low toxicity in a Hippocratic 
screens at doses of 200 and 400 mg per kg body weight in animal models (Pisha et al., 1995). 
In a study published by Pisha, intraperitoneal application of acid 1 to mice in six doses of 
500 mg/kg every fourth day and six doses of 250 mg/kg every third day were accepted 
without any signs of toxicity (Cichewicz & Kouzi, 2004). In vitro studies showed that the 
only symptom of high doses of acid 1 was an increase of intracellular-free calcium, and this 
increase was only associated with a small decrease in cell viability (Cichewicz & Kouzi, 
2004). Very low toxicity and significant antitumor activity give acid 1 a very favorable 
therapeutic index (Cichewicz & Kouzi, 2004). These findings thrust common triterpenes - 
betulinic acid (1) - to the center of interest within scientific groups studying antitumor 
activities and mechanisms of action, and pharmaceutical companies interested in 
chemotherapeutics (e.g. BMS). 
Other anticancer activities and studies 
Acid 1 has presented promising antitumor activity against a variety of tumor cell lines such 
as malignant brain-tumor (Fulda et al, 1999), neuroectodermal (Zuco et al., 2002), human 
chronic myelogenous leukemia (CML) 562 (Gopal et al., 2005) and many other cell lines 
derived from the most prevalent human cancer types (lung, colorectal, breast, prostate and 
cervical cancer (Kessler et al., 2007; Zuco, 2002). Furthermore selective cytotoxicity against 
tumor cell lines in comparison with normal cells has been confirmed (Hata et al., 2002). 
Pulsatilic acid (2), a compound isolated from Pulsatilla chinensis is another example of a 
triterpene highly cytotoxic against mouse melanoma cell line B16 (Bi et al., 2007; Liu et al, 
2004; Zhou et al., 2007). Pulsatilic acid (2) is a little less active than acid 1 (53 mol/L for acid 
1 and 83 mol/L for acid 2) (Bi at al., 2007). 
The last type of natural pentacyclic triterpenes active against melanoma are ochraceolides, 
compounds with modified E-ring. Ochraceolides A (6) and C (7) were isolated together with 
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other lupane derivatives from Kokoona ochracea and their activity against line UISO-MEL-2 
was approximately 15 mol/L (Ngassapa et al., 1991). 
Synergisms of acid 1 with cytostatics and other effects.  
Animal and cell based studies (Sawada et al., 2004; Selzer et al., 2000; Wachsberger et al., 
2002) have focused on investigating the synergic anticancer activities of various doses of 
acid 1 and vincristine (Fig. 8), radio therapy, lowering pH, or hyperthermia. A significant 
increase in the efficiency of radio therapy against human melanoma cells was demonstrated 
when combined with dossing of betulinic acid (1). Response of melanoma cells to betulinic 
acid (1) alone or in combination with irradiation was studied by Selzer and co-workers 
(Selzer et al., 2000). Analysis of tumor cell survival following the treatment by acid 1 
combined with an application of ionizing γ irradiation (dose of 2 Gy, within the range used 
in clinical therapy) indicates that betulinic acid (1) and irradiation have an additive effect on 
the inhibition of colony-forming ability. It is possible that acid 1 can target tumor cells that 
are resistant to ionizing radiation. 
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Fig. 8. Vincristine 
In another study, Japanese authors looked at the influence of combination of betulinic acid 
(1) and vincristine on mice melanoma B16F in vitro and in vivo (Sawada et al., 2004). Based on 
fast apoptosis of those melanoma cells, the authors suggested an existence of a synergic 
effect between acid 1 and vincristine, they found, that each substance causes inhibition of 
cell cycle in different phases: betulinic acid (1) in G1 phase and vincristine in G2/M phase 
(Sawada et al., 2004). An application of both compounds in vivo increased suppression of 
lung metastasis of melanoma cells in a model C57BL/6 in mice, in comparison to vincristine 
only. Authors proclaimed that acid 1 is a suitable complement to the chemotherapy of 
malignant melanoma (Sawada et al., 2004).  
Wachsberger et al reported an influence of antitumor activity of compound 1 together with 
application of hyperthermia and lower pH in human melanoma cells DB-1 (Wachsberger et 
al., 2002). They found that percentage of survived tumor cells during the combined 
application of acid 1 and hyperthermia of 42°C for two hours decreased with respect of used 
pH 7.3, 6.7 and 6.3  from 5 %, 9 %, to 2 %. 
In vivo studies and the clinical trials of betulinic acid (1) 
Based on promising in vitro and in vivo activity of betulinic acid (1) in melanocarcinoma cells 
and tumors in animal models, human clinical trials were induced. Some considerations were 
taken in regard to actinic keratosis (AKs), which represents the initial intraepidermal 
manifestation of keratinocyte abnormal transformation that may potentially progress to 
small cell carcinoma. In a randomised trial, Huyke (Huyke et al., 2009) treated 45 patients 
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(with <10 AKs each) either with a topical betulin-based oleogel twice daily, or cryotherapy, 
or a combination of the two. Treatment with betulin-based oleogel was well-tolerated and 
showed efficacy in treating AKs. Continued controlled studies on larger sample sizes 
investigating the use of betulinic acid for the treatment of nonmelanoma skin cancer are 
warranted. Phase I and II clinical trials evaluating the topical application of betulinic acid (1) 
in the treatment of dysplastic nevi with moderate to severe dysplasia are currently ongoing 
(www.clinicalstrials.gov). Clinical trials with acid (1) have not been completed to date. 
Overview of other biological activities of acid 1 
It should be stated that betulinic acid (1) also has other interesting biological activities, 
especially, anti-HIV (Fujioka et al., 1994; Mayaux et al., 1994) and anti-inflammatory (Huang 
et al., 1995; Mukherjee et al., 1997; Recio et al., 1995a, 1995b; Yasukawa et al., 1991). The anti-
HIV activity of betulinic acid (1) and its derivatives was first described by two independent 
research groups (Fujioka et al., 1994; Mayaux et al., 1994). Since then, several researchers 
prepared, published and often patented a large number of novel derivatives (Jacob et al., 
2010; Salzwedel et al., 2010) with significant activity against HIV (EC50 < 1 nM). Among 
these derivatives, three main groups are worth mentioning. First 3-O-acyl derivatives of 
betulinic acid that inhibit the maturation of HIV virus (Kashiwada et al., 1996). 3-O-3´,3´-
dimethylsuccinylbetulinic acid (8), also known as PA-457 or bevirimat is the most important 
representative of this group.  
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Fig. 9.  
The companies Panacos (Salzwedel et al., 2010) and Myriad (Jacob et al., 2010) found 
bevirimat to be active against HIV in vivo which sent the compound to phase IIa of clinical 
trials under registry number NCT01026727 (US National Institute of Health). Not only does 
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Bevirimat (Jacob et al., 2010; Kashiwada et al., 1996; Salzwedel et al., 2010) show very high 
anti-HIV activity (EC50 ~ 0.35 nM) but it also has a very low toxicity (typical for betulinic 
acid derivatives) which together puts the value of its therapeutic index over 20,000. Another 
advantage of bevirimat is that to date no resistance to it has been recorded. The second 
group of anti-HIV active compounds are 28-amides (Evers et al., 1996; Soler et al., 1996; Sun 
et al., 2002) of betulinic acid that block the entry of the virion into cells. The most important 
amide derivatives (Holz-Smith et al., 2001; Sun et al., 2002) are compounds 9 and 10 also 
known as RPR103611 and IC9564. The third group is represented by compounds that 
combine both of the previously mentioned mechanizms of activity (Huang et al., 2006) 
because they contain a combination of both pharmacophors – acyl group in the position 3 
and 28-amide group. Those compounds were discovered most recently and the most active 
is ([(N-[3-O-(3´,3´-dimethylsuccinyl)lup-20(29)-en-28-oyl]-7-aminoheptyl)-carbamoyl]me-
thane) (11) which showed activity about 20 times higher than Bevirimat in in vitro tests 
(Huang et al., 2006).  
Yasukawa was the first to describe anti-inflammatory activity of betulinic acid (1) 
(Yasukawa et al., 1991) and relevant inhibition effect against TPA –induced inflammation 
was found at concentration of 5 M (Huang et al., 1995; Mukherjee et al., 1997; Recio et al., 
1995a, 1995b). Promising anti-inflammatory activity has also been found in 3caffeoyl 
betulinic acid (12) by Fuchino group (Fuchino et al., 1995, 1996, 1998). This compound is one 
of the components of birch bark. Last but not least, betulinic acid (1) is commonly used in 
the cosmetic industry. It is usually used in concentrations of 50-500 mg per gram to prevent 
and help treat UV-induced skin cancer, to reduce signs of cellulitide and to stimulate 
collagen synthesis in skin-care products. It’s also used to prevent sunlight-caused signs of 
aging, wrinkles, and blotches and to improve skin homogeneity and pigmentations. 
(Bradbury et al., 1997a, 1997b, 1997c) 
2.2 Semi-synthetic triterpenoids with activity against melanoma 
The very poor solubility of acid 1 in water based media (< 1 mol/L) (Cichewicz & Kouzi, 
2004; Symon et al., 2005), high hydrophobicity (log P) (Srivastava et al., 2002) and unsuitable 
pK parameters (absorption, distribution, metabolism and elimination), along with strong 
antitumor potential (Pisha et al., 1995) and low acute toxicity (Cichewicz & Kouzi, 2004) 
motivated a number of scientific institutions to synthesize derivatives, pro-drugs and 
formulations of betulinic acid (1) that could retain the activity and low toxicity, but improve 
the afore mentioned properties. The following semi-synthetic derivatives might be divided 
into three groups: simple derivatives of natural triterpenes (2.2.1), derivatives obtained by 
biotransformation procedures of betulinic acid (1) (2.2.2) and triterpenoids with 
modification of lupane skeleton (2.2.3). 
2.2.1 Derivatives of natural triterpenes (acids 1, 2 and betulin (3)) 
Several functional groups can be used for the derivatization of acid 1, such as the secondary 
hydroxyl group in the position 3, a neopentyl 28-carboxyl moiety in the location 17 and 
finally, a double bond located between carbons 20 and 29. As both hydroxyl and carboxyllic 
groups are sterically hindered, common derivatization processes usually don’t work very 
well or fail completely. A typical example is the esterification of 28-carboxylic group. The 
reaction does not work with alcohols at all; acid catalysis or use of DCC does not help either. 
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Using alkyl bromides or iodides and alkali carbonates or DBU as the basis in DMF are the 
most effective conditions to introduce an ester to 28-carboxyl group. Analogously, simple 
alkali hydrolysis of alkyl betulinates does not work and to release a free acid from its ester, it 
is necessary to apply drastic conditions such as reflux with potassium hydroxide in ethylene 
glycol or nucleophilic deprotection using lithium iodide in collidines under reflux. For the 
purposes of this chapter, the compounds that are modified at more than one site of the 
skeleton are classified according to significance of the modification. Also, many cytotoxic 
compounds with no data about their activity on melanoma lines are not included in this 
chapter. 
Derivatization of betulinic (1) and pulsatillic acid (2) in position 28 
Cytotoxicity of various types of esters of betulinic acid (1) is very well researched. In the 
past, researchers found that the cytotoxicity of betulinic acid decreases by forming alkyl or 
aryl esters from 28-carboxylic group. (Kim et al., 1998, 2001; Kvasnica et al., 2005; Urban et al., 
2004, 2005). One of the explanations of this fact is that free carboxyl group is responsible for 
the activity and the hydrolysis of its esters is extremely difficult and requires extreme 
conditions which are caused by sterical hinderance of the neopentyl-type group. Curiously, 
difficulties with the hydrolysis were not observed at similar -unsaturated esters (e.g. 
compound 13, Fig. 10) (Sarek et al., 2005) which suggests that a different reaction mechanism 
might exist to cleave them, so those difficulties are probably specific for alkyl and aryl esters 
and for acids with unmodified E-ring. Very detailed studies of the dependency of 
cytotoxicity on the type of the ester in position 28 of betulinic acid (1) have been published 
in literature (Kvasnica et al., 2005; Urban et al., 2005) The authors demonstrated that methyl, 
ethyl, and benzyl esters are an order of magnitude less active than the free acid 1.  
A different situation was observed at substituted alkyl esters of acid 1 and 2 (Bi et al., 2007; 
Urban et al., 2005). Urban et al. compared the cytotoxicity of methyl-, pivaloyloxymethyl-, 
and acetoxymethyl- esters of betulinic and betulonic acid 15 - 22 on broad scale of cancer cell 
lines. They found that while methyl- and pivaloyloxymethyl- group significantly decrease 
the activity, the Acm-esters were either as active as the starting acids or better. The Acm 
group is therefore a suitable derivatization group that could possibly be useful to synthesize 
prodrugs. Another good property of Acm is that it increases hydrophilicity.  
A completely new type of esters was published by Effenberger et al. who synthesized esters 
from a variety of monoterpenes, sesquiterpenes, and betulinic acid with carboxylic and 
hydroxyethylene derivatives of thymoquinone (Effenberger et al., 2010). However, 28-esteric 
derivative 23 was about 7 times less active against the cell line 518A2 than the free acid 1 
(Effenberger et al., 2010). A SARS study done by Bi et al. who investigated the activity of 
alkenyl, alkynyl and hydroxyalkyl esters of pulsatillic acid 24 - 29 against several tumor cell 
lines. The authors included in vivo experiments using the most active allyl ester 24 and the 
starting acid 2 on mice in H22 and B16 models. The in vitro experiments showed that all 
prepared esters were more active than the starting acid 2 against line B16 and also that 6-
hydroxyethylester was only slightly better than the acid 2 on the same line. In vivo 
experiments brought even more exciting results when they showed that allyl pulsatillate 24 
(applied as intraperitoneal DMSO solution) caused a larger reduction of the mass of a tumor 
than the free acid 2. Its activity was actually comparable to cyclophosphamide which is a 
commercially used cytostatic.  
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Fig. 10.  
Willmann et al. brought even more promising results using the compound 30 - NVX-207 that 
is an ester of acetylbetulinic acid with tris(hydroxymethyl)aminomethane (TRIS). The 
compound was highly active in vitro against 15 cancer cell lines including human melanoma 
518A2 and the activity was between 2.6 mol/L on 518A2 and 5.6 mol/L on fibrosarcoma 
HAT 1080. Those initial experiments were followed by a phase I/II animal clinical study on 
canine patients with spontaneous currently untreatable tumors using intralesional and 
surrounding tissue application of NVX-207. Five dogs bearing tumors of different 
histogenetic origine (squamous cell carcinoma, soft tissue sarcoma, mammary carcinoma 
and adenocarcinoma of the scent gland of the paw) were treated. The complete response to 
the therapy was observed in two dogs, almost complete remission (90% reduction), stable 
disease (50% response) and 30% percent reduction was observed in the remaining cases. No 
systemic side effects and minor local side effects (mild local discomfort) after infiltration of 
the tumors were observed (Willmann et al., 2009). 
Another large group of activated esters are esters with sugars, sometimes improperly called 
glycosides. The cytotoxicity of these compounds has not been studied thoroughly and the 
few examples in literature (Gauthier et al., 2009a, 2009b; Pakulski et al., 2009) do not show 
activity against melanoma cell lines. The only conclusion that can be made is that esters 
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where a terpene is connected to a single saccharide unit are far less active than the free acid. 
An example of this is - -D-glucopyranosyl betulinate (31) (Gauthier et al., 2009a, 2009b) 
which has activity lower than the activity of betulinic acid (1) by an order of magnitude. 
Despite this, a study which researched the cytotoxicity of bidesmosidic saponines showed 
that the saccharide component bound as an ester is an important part of the pharmacophore 
because its removal caused significant drop of activity. The study contained pulsatillic 
glycosides 32 isolated from Schefflera rotundifolia (Cioffi et al., 2003). 
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Amides represent another type of carboxylic acid derivative. Their antitumor activity is 
usually high and their hydrophilicity makes their use in in vivo tests very easy (Jeong et al., 
1999; Willmann et al., 2009). Jeong published a very complex SARS study about the cytotoxic 
activity of conjugates of betulinic acid (1) with natural amino acids along with a toxicity 
study on fibroblasts and basic studies of solubility. The best results against MEL-2 cell line 
were found using conjugates of betulinic acid with alanine - 33 and 35; although the 
compounds were somewhat toxic against fibroblasts. While the conjugates of betulinic acid 
with valine 34, 37 and glycine 36 were less active than those with alanine 33 and 35; they 
were completely non toxic. The glycine conjugate 36 was also the most hydrophilic of the 
studied compounds. The authors tested the solubility of the conjugates with a very simple 
method. They prepared solutions of each studied compound in DMSO and kept diluting 
those solutions with water until they started to precipitate. While the most active alanine 
derivative 33 could be diluted up to 50 times, the glycine conjugate 36 could be diluted 100 
times. Despite the fact, that the cytotoxicity of the glycine conjugate 36 was the same as the 
activity of free betulinic acid (1) (4.2 mol/L), the conjugate 36 is far more soluble in water 
and that makes it a very suitable candidate for in vivo testing.  
Another type of derivative that showed cytotoxicity against melanoma lines was quaternary 
ammonium salts (Biedermann et al., 2010; Sarek et al., 2008). The strong antitumor activity of 
quaternary ammonium salts of four terpenic acids (betulinic (1), dihydrobetulinic (38), 
platanic (39) and 21-oxoacid 14) on a panel of 11 cancer cell lines has been demonstrated in 
the literature (Sarek et al., 2008). The salts were obtained by a two step reaction of a terpenic 
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acid with 1,2-dibromoethane followed by a quaternization with a corresponding amine 
(trimethylamine, triethylamine, pyridine). The best cytotoxicity was obtained with 
quaternary salts of triethylamine - compound 40 and 41. The dihydrobetulinic salt 41 is 
currently being tested on melanoma lines and has shown activity between 1.6 mol/L 
against the line UAAC 62 and 14.6 mol/L against the line M14 (see Tab. 4). Salts 40 and 41 
are also very hydrophilic which makes it easy to dissolve them (55 mg/mL of vehiculum) in 
media based on water and moreover, their oral accessibility makes them ideal candidates for 
in vivo testing on animals.  
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The final group of carboxylic derivatives consists of compounds with aldehydic or 
hydroxymethyl group in position 17 because they can be prepared by simple reduction step 
from carboxylic acids. Those compounds are actually more easily synthesized from betulin 
(3) than from betulinic acid (1). It was shown that the carbonyl group (aldehyde or 
carboxylic acid) is essential for cytotoxicity because while aldehydes are active, 28-
hydroxyderivatives are generally not. This fact was well documented in the work (Hata et 
al., 2003) in which betulinal (4) had activity 10.6 mol/L, and acid 1 6.5 mol/L against 
melanoma cell line SK-MEL-2. However, if another part of the molecule of 28-
hydroxyderivatives is modified, the activity may increase. The best examples are glycosides 
of betulin (3) that are very active on melanoma B-16F, especially when position 3 was 
glycosylated. Curiously, 28-O-glycosides were inactive (Gauthier et al., 2006). Among -D-
glucoside, -D-arabinoside, and -L-rhamnoside 42 – 44 (Fig. 13), the last listed was the most 
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active against B16-F1 cell line (18 mol/L, which is just slightly worse than acid 1 with an 
activity of 16 mol/L) (Gauthier et al., 2006). There are no results for bisdesmosidic 
saponines on melanoma cell lines, however, work of Gauthier describes similar trend on 
another lines (most active is betulin-328-O-bis(-L-rhamnoside) 45 (Gauthier et al., 2009a). 
 
R2O
42: R1 = O-L-Glc,     R2 = H
43: R1 = O-L-Rha,    R2 = H
44: R1 = O-D-Ara,     R2 = H
45: R1 = O-L-Rha,    R2 = L-Rha
L-Rha
O
HO
HO
OH
O
OH
HO
OH
D-Ara
O
CH2OH
OH
OH
HO
D-Glc
R1
 
Fig. 14. 
 
R1O N
+
N
X =
46: R1 = OCOCH2X+Br-;            R2 = OH
47: R1 = OCO(CH2)3X+Br-;        R2 = OCOCH2)3X+Br-
48: R1 = OCOCH2X+Cl-;            R2 = OH
49: R1 = OCO(CH2)2X+Cl-;        R2 = OCO(CH2)2X+Cl-
50: R1 = OCOCH(C2H5)X+Br-;  R2 = OCOCH(C2H5)X+Br-
51: R1 = OCOCH(CH3)X+Cl-;    R2 = OCOCH(CH3)X+Cl-
52: R1 = OCOCH2X+Cl-;            R2 = OCOCH2X+Cl-
53: R1 = OCOCH2X+Br-;            R2 = OCOCH2X+Br-
54: R1 = CONHCH2CH3;           R2 = OCONHCH2CH3
55: R1 = Ac;                               R2 = OH
56: R1 = H;                                 R2 = OAc
57: R1 = Ac;                               R2 = OAc
R2
 
Fig. 15. 
Dimethylaminopyridine quaternary ammonium derivatives of betulin 46 – 53 showed 
strong activities of 0.3 - 2.6 mol/L on cell lines WM3211 a WM793 and again, the 3,28-
bisfunctional derivatives were more active than the monofunctional (Holy et al., 2010). Also 
bis(carbamoyl) derivatives had strong activity against 518A2 when bis(ethylcarbamate) 54 
was almost as active as betulinic acid (1) (about 8 mol/L). Common acyl derivatives such 
as 55 - 57 acetates cause a complete extinction of any cytotoxic activity (Gauthier et al., 2006). 
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Derivatization of betulinic acid (1) and betulin (3) in position 3
This heterogeneous group of derivatives contains C-3 glycosides, 3-O-acyl derivatives, 3-
oxo compounds and their derivatives (ketones, oximes), and products of reduction of 
nitrogen derivatives (3-amines). As already mentioned in the previous chapter, antitumor 
activity of triterpenoid saponins is relatively well explored (Gauthier et al., 2006, 2009a, 
2009b; Pakulski et al., 2009; Thibeault et al., 2007) however there is not much data for the 
melanoma line (Gauthier et al., 2006; Pakulski et al., 2009). 
The situation with betulinic acid 3-glycosides reminds the situation with esters of betulinic 
acid (1) with sugars. 3-O--L-rhamnopyranoside 59 is the most active glycoside with 
activity of 3.9 mol/L against metastatic murine melanoma line B-16F1. Glycoside 59 is 
approximately 4 times more active than acid 1 itself (Gauthier et al., 2006). Approximately 
the same activity as betulinic acid (1) was found in case of its 3-O--D-arabinopyranoside 
60, while 3-O--D-glucopyranoside 58 was 2 times less active than the 3-O--L-
rhamnopyranoside 59 (Gauthier et al., 2006). In the same work, an inverse relation for 
glycosides of methyl betulinate (15) is also documented; 3-O--glucopyranoside 58 was the 
most active from them. (Gauthier et al., 2006) 
(Pakulski et al., 2009) investigated the antitumor efficacy of mannopyranosides and 3,6-
branched trimannopyranosides, which were stereoselectively prepared from the natural 
triterepenes – betulin (3), and betulinic acid (1). Although it is a synthetically attractive 
method, the mannosylation did not bring any significant effect against melanoma. 3-O--D-
mannopyranoside 61 and 28-O--D-mannopyranoside 62 showed very poor results against 
malign melanoma line G 361 and trimannopyranosides were not active as well. 
2-Deoxygalactosides and 2-deoxyglucosides (Sarek et al., 2009), prepared from a large group 
of highly oxidized lupane hydroxyderivatives by stereospecific additions of corresponding 
glycals, have significant antitumor activity. The above mentioned 2-deoxyglucosides were 
effective against a wide range of cancer cell lines, including MDR (Sarek et al., 2009). 
Recently, we tested the anticancer effectiveness of derivative 64 against melanoma lines 
where activity reached approximately 20 mol/L (Tab. 4). This group of saponins is 
promising because peracetylated analogues have an order of magnitude better activity than 
free 2-deoxyglycosides (Sarek et al., 2009). 2-deoxyglycosides are very hydrophilic in 
character which makes them readily soluble in aqueous media and easily applicable in in 
vivo conditions, e.g. compound 64 up to 68 mg/mL (Sarek et al., 2007). It was shown on mice 
that 2-deoxyglycosides are orally bioavailable which is possibly result of their hydrophilicity 
(Sarek et al., 2007), and that makes them promising candidates for anticancer drugs. An 
example of a natural highly active glycoside of betulinic acid is 3-O--L-arabinopyranoside 
63 isolated from Schefflera rotundifolia, which has an activity of 0.55 mol/L against mouse 
fibrosarcoma line and also shows a combination of glycoside and saccharide ester in 
molecule. 
Acyl derivatives of betulinic acid (1) and betulin (3) are a large group of semisynthetic 
derivatives known especially for their antiviral effects while their cytotoxicity is much lower 
than that of hydroxyderivatives. This fact dramatically improves their therapeutic index for 
testing anti-HIV activity (Krasutsky et al., 2006; Fujioka et al., 1994, Mayaux et al., 1994). A 
comparison of activity of betulinic (1) and dihydrobetulinic acid (38) with their acetates is 
described in (Kim et al., 2001; Mukherjee et al., 2004). Tests with SK-MEL-2 and M14-MEL 
lines showed that the acetylation of hydroxyderivatives causes either a small decrease or no 
change in cytotoxicity (Kim et al., 2001). This fact is in good agreement with the work, where 
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the influence of the 3-O-acetyl group on cytotoxicity of broader group of triterpenoides 65 
– 67 was studied (Mukherjee et al., 2004; Sarek et al., 2005). In the work of Chien et al., the 
cytotoxicity of natural 3-O-acyl derivatives of betulinic acid 68 – 71 isolated from Strychnos 
vanprukii Craib was investigated against MEL2 line. Cytotoxicity of feruoyl 68, 69 and 
coumaroyl 70, 71 derivatives was approximately 3 times worse than the free acid 1 (Chien et 
al., 2004). 
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The last type of 3-O-acyl derivatives of betulinic acid (1) with described cytotoxicity against 
the human melanoma line SK MEL2 is represented by phthalates 72 - 74 prepared by 
(Kvasnica et al., 2005). A SARS study (Kvasnica et al., 2005) of cytotoxicity of hemiphthalates 
and phthalates of betulinic acid (1) and betulin (3) and their esters against SK MEL2 line 
shows that the more lipophilic the phthalate ester is, the more active the hemiphthalate is 
and thus the difference in the activities of the ester is higher. The best activity was reached 
by derivatives 72 and 74 which was 10 times more active than benzyl betulinate (17) (Fig. 9) 
itself and a little more active than the free acid 1. Another convenient feature of 
hemiphthalates is their high hydrophilicity allowing their easy dissolution in aqueous 
media and their use in in vivo tests (Krasutsky et al., 2006; Sarek et al., 2007). 
The final group consists of derivatives of 3-oxo acids 5, 75, 76 and their mostly nitrogenous 
analogues 77 - 81. It is known that oxidation of the 3-hydroxy group to the oxo group 
increases the cytotoxicity against the human melanoma line MEL-2. (Kim et al., 1998) While 
in the pair of betulinic acid (1) - betulonic acid (5) the change is relatively insignificant (1.2 
vs. 0.9 mol/L), the difference is almost an order of magnitude (5.8 vs. 0.7 mol/L) large in 
the case of dihydrobetulinic acid (38) - dihydrobetulonic acid (75), which makes 
dihydrobetulonic acid (75) about twice more effective against MEL-2 than betulinic acid (1) 
itself (Kim et al., 1998). Analogous results were obtained in cytotoxicity tests of oxidation 
products of pulsatillic acid (2) (Liu et al., 2004; Zhou et al., 2007). Pulsatillonic acid (76) 
showed higher activity against B16 line than the original pulsatillic acid (2) (Liu et al., 2004; 
Zhou et al., 2007). Oxime derivatives of both acids 77 and 80 showed the cytotoxicity against 
MEL-2 an order of magnitude lower than oxo acids 5 and 75, methyloxime analogues 78 and 
81 were two orders of magnitude less active (Kim et al., 1998). In contrast, the 3-amino 
analogue 79 obtained by reductive ammination of betulonic acid (5) showed anti-MEL-2 
activity comparable with betulinic acid (1) (Kim et al., 1998). The nitrogenous derivatives of 
betulinic acid (1) in position 3 can also include carbamoyl derivatives 82 – 84 synthesized 
according to the literature (Kommera et al., 2010). While the 3-phenylcarbamoyl derivative 
of betulinic acid - 83 - was active against 518A2,  3-ethyl carbamates 82, 84 showed activity 
comparable to or better than betulinic acid (1). Strong antitumor activity against a radial-
phase WM3211 and a vertical-phase melanoma WM793 was also found in the case of the 
quaternary salt 85 with DMAP, with activity 2.6 respectively 5.7 mol/L. 
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Fig. 18. 
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Modification of skeleton of betulinic acid (1) on the isopropenyl side chain 
An addition of hydrogen, respectively hydrogenation of 20(29)-double bond, represents the 
simplest modification on the isopropenyl side chain as well as a simple way to isotopically 
label the terpenic skeleton with either deuterium or tritium. Although the hydrogenation of 
a terminal double bond seems easy to be done, experiments show the contrary, because 
20(29)-double bond is disubstituted. Under the standard conditions – using hydrogen on 
Pd/C, it is possible to achieve a selective debenzylation of benzyl betulinate (17), without 
20(29)-double bond to be hydrogenated (Kvasnica et al., 2005). As mentioned above, 
dihydrobetulinic acid (38) is approximately four times less active than betulinic acid (1) 
against the line MEL-2, whereas the cytotoxicity of oxidized forms, such as dihydrobetulonic 
(75) and betulonic acid (5) is almost identical. These data show that 20(29) 
dihydroderivatives are comparably active to their unsaturated analogs (Biedermann et al., 
2010; Sarek et al., 2007). 
Among the other explored addition reaction to 20(29)-double bond, there is the addition of 
halogene (Mukherjee et al., 1997) or dihalocarbene (Symon et al., 2005). In the study of 
Mukherjee’s et al., cytotoxic activity (except melanoma lines) of the products of addition of 
bromine to betulonic (5), betulinic (1), and acetylbetulinic (65) acids (e.g. 86 – 87, Fig. 19) was 
explored and the best results were achieved using 20,29–dibromo-3-O-acetylbetulinic acid 
(87) which activity was about the same as betulinic acid (1). A Russian team tested the 
activity of formerly prepared addition adducts 88 and 89 of dichloro- and dibromocarbene 
to betulinic acid (1) against human melanoma cells Colo 38 and Bro.92. The best results were 
achieved with a dichloroderivative 88 with the activity on Bro line slightly better than the 
activity of acid 1, nevertheless the authors claimed that the high lipophilicity of synthesized 
derivatives complicated in vitro tests, therefore further tests of the derivatization of these 
non-polar compounds were suggested (Symon et al., 2005). 
Another option to modify the isopropenyl side chain is substitution, respectively allylic 
oxidation. Introducing alcohol moieties into the location 30 might be carried out either by 
allylic bromination using NBS followed by nucleofilic substitution (Kim et al., 2001) or allylic 
oxidation followed with reduction (Biedermann et al., 2005). The most unique compound 
among these oxygenated derivatives is the unsaturated aldehyde 90, synthesized by allylic 
oxidation of acid 1 by selenium dioxide. Aldehyde 90 disposes of strong multispectral 
antitumor activity, including melanoma lines B16, B16F, SK-MEL2 a MEL-3 (9.3, 12.4, 17.7 
and 3.7 mol/L; also see Tab. 4), and except for B16F, it is several times stronger than acid 1 
(Sarek et al., 2003). Corresponding allylic alcohol 91 and its methyl ether 92 had a similar 
acitivity of 20 mol/L on SK-MEL2 lines (Kim et al., 2001). 3,30-Diamino derivatives 
synthesized by (Mar et al., 2010) showed strong proapoptotic effect against panel of seven 
tumors lines, include SK-MEL-2. Derivative 93 was reported to have two times better 
cytotoxic effect against SK-MEL2 than acid 1 itself and furthermore this compound is highly 
hydrophilic and therefore it is easily applicable for in vivo tests (Mar et al., 2010). 
Finally, compounds formed by oxidative cleavage of the double bond 20(29) should be 
mentioned (Kim et al., 2001). Evaluated anti SK-MEL2 activity of platanic acid (39) (and its 
derivatives), obtained by the oxidative cleavage of the double bond using ruthenium 
tetraoxide (which provide mostly products expected from ozonolysis under standard 
conditions) was published in Kim’s study. Platanic acid (39), alcohol 94 and oxime 95 did 
not show significant cytotoxicity on SK-MEL2 (Kim et al., 2001). 
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Fig. 19. 
2.2.2 Derivatives obtained by biotransformation procedures of betulinic acid (1) 
Several papers have described the biotransformation (Chatterjee et al., 1999, 2000; Kouzi et 
al., 2000) of betulinic acid (1) and the biological activity of those biotransformation products 
96 - 102. In Fig. 20, the biotransformation products of different bacterial strains are clearly 
shown. 
The bacterial biotransformation usually produces compounds that would be very difficult to 
obtain using classical chemical approaches. An example of such compounds is a group of 
hydroxyderivatives with hydroxyl groups in positions 1, 6, 7, 11 and 15, sometimes the 
hydroxylation is accompanied by an oxidation in position 3 or an esterification in position 
28 by the glucopyranosyl residue. Monohydroxyderivatives 99, 100, as well as betulonic acid 
(5) showed an order of magnitude better activity during cytotoxicity screening against the 
Mel-2 cancer line (pleural fluid) than betulinic acid (1) itself, whereas their activity against 
the Mel-1 cancer line (lymph node) was an order of magnitude worse. 1,7-
Dihydroxyderivative 102, 6,7-dihydroxyderivative 98, and 7,15-dihydroxyderivative 96 as 
well as 7-hydroxyderivative 97 (Kouzi et al., 2000) or glucopyranosyl ester 101 did not show 
any significant activity against either Mel-1 or Mel-2 cancer lines. 
These SARS studies of biotransformation products of acid 1 show that the hydroxylation of 
the lupane skeleton has a positive impact on antimelanoma activity only if it does not occur 
in position 7 or 15. Inactivity of -D-glucopyranosyl ester 101 is possibly caused by the 
difficulties with hydrolysis of this ester function. 
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Fig. 20. Biotransformation of betulinic acid (1) 
2.2.3 Triterpeoids with modification of lupane skeleton (at ring A or E) 
Oxidative modification and cleavage on A-ring of betulinic acid (1) 
A detailed study of the cytotoxicity of the products of oxidation of betulinic acid (1) on A-
ring was published in paper (Urban et al., 2004). The authors firstly oxidized betulinic acid 
(1) using chromium(VI) oxide to obtain betulonic acid (5) that was further oxidized with air 
or oxygen in the presence of potassium tert-butoxide in tert-butylalcohol. That way, either 
diosphenol 103 or lactol 105 was obtained. Diosphenol 103 was then oxidized with 
hydrogen peroxide in basic conditions to give A-seco triacid 106, reduction of this triacid 
afforded A-seco triol 107 and dehydratation of the same triacid gave a 7-membered 
anhydride 108 (Urban et al., 2004). Curiously, diosphenol 103 only occurs in its enolfom 
which had not been known before as some literature displays it as a diketone structure that 
actually does not exist. Derivatives of diosphenol 103, A-seco triol 107 and 7-membered 
anhydride 108 were the most cytotoxic active compounds from this group. Their 
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cytotoxicity was firstly measured on five cancer cell lines (none of them melanoma) and the 
active derivatives of diosphenol 103 was then tested on three more lines including human 
melanoma SK-Mel2. More recent tests of the diosphenol derivatives 104 against three 
melanoma lines in groups of Sarek and Hajduch resulted in activity about 7-10 times worse 
than betulinic acid (1). Tab 4. 
 
CO2R
O
RO
103: R = H
104: R = CH3
O
CO2H
O
OH
105
R
R
R
106: R = CO2H
107: R = CH2OH
CO2CH3
O
O
O
108
 
Fig. 21. 
Condensation reactions at A-ring 
This special chapter will discuss aldehydes and -ketoesters, the products of Claisen 
condensation of triterpenoid 3-oxoderivatives with formates and carbonates. Both aldehydes 
and -ketoesters are in their enolforms probably due to the boat conformation of the A-ring. 
Those -dicarbonyl compounds are a good starting material for synthesis of various 
heterocycles and for many other substitution reactions. A very complex evaluation of activity 
of A-homo derivatives was published in work (You et al., 2003). Probably the most interesting 
was 109 a cytotoxic lupane analogue of a promising anticancer drug CDDO, mainly because 
it’s structural motif seems to be the universal pharmacophor of the cytotoxicity in pentacyclic 
triterpenes (Suh et al., 1999; You et al., 2003). This derivative is the most active compound from 
a group of three very promising structures – chloroderivative 110, aldehyde 111, and nitrile 
109, which activities against melanoma cell lines SK-MEL-2 a B16-F10 were an order of 
magnitude better than the activity of betulinic acid (1) (You et al., 2003). These compounds are 
actually also an exemption from the rule that the 28-alkyl esters are inactive because prepared 
methyl esters are almost as active as free acids (You et al., 2003).  
Heterocyclic derivatives are another type of compounds with homologous carbon atoms 
bound to the A-ring of the terpenic skeleton (Kumar et al., 2008; Urban et al., 2007; You et al., 
2003). You et al. published results of the testing of cytotoxic activity of four isoxazole 
derivatives 112 – 115, prepared by a condensation of aldehydes with hydroxylamine against 
cell lines SK-MEL-2 a B16-F10. The isoxazoles were strongly cytotoxic only when 28-
carboxylic acid was free (compounds 112 and 114). In an article (Urban et al., 2007), a 
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Fig. 22. 
synthesis of triterpenoid pyrazines from betulonic (5) and dihydrobetulonic acid (75) and 
their cytotoxic activity on 9 cancer cell lines including SK-MEL2 was published. The 
compounds were obtained by a reaction of 3-oxoacids with ethylenediamine, followed by 
aromatization of the intermediate dihydropyrazine (Urban et al., 2007). Despite the fact that 
these pyrazines (e.g. 116) were more cytotoxic against many cancer cell lines than betulinic 
acid (1), they were four fold less active against the melanoma cell line SK-MEL2. A 
conclusion is ambiguous, a 2,3 annealing of a pyrazine cycle to the lupane skeleton increases 
the cytotoxic activity against some cancer cell lines while vanishes the activity against 
others, such as melanoma (Urban et al., 2007). Analogous quinoxalines (benzopyrazines) 
were inactive at all. Urban et al. also confirmed that there is a strong dependence of the 
cytotoxicity on the type of ester at 28 carboxylic group. As mentioned before, the Acm esters 
were generally as active as free acids. Another kind of heterocycles were described in work 
(Kumar et al., 2008), who prepared and performed a large SARS study with 2,3-annealed 
indole derivatives of betulinic (1) and betulonic acid (5), prepared by Fisher reaction. The 
article contains over 30 indole derivatives that were tested on a panel of 8 cancer cell lines, 
however, not including melanoma. Despite that, a general conclusion can be made that an 
introduction of the indol heterocycle to a terpene improves the cytotoxicity when both N-1 
and C-28 positions remain free. An exception from this assumption is the most active 
derivative 117 (Kumar et al., 2008) which is conjugated with glycine through C-28 but that is 
not surprising with respect to high activity of compound 36. 
 
N
H
O
NHCH2CO2H
117  
Fig. 23. 
Modification of the ring E 
First semi-synthetic anticancer lupane and 18,19-seco lupane derivatives with modified 
ring E (referred to as Betulinines) to be published were compounds derived from 18-lupene 
that contained either intact E-ring and oxygen functional groups in the positions 21 and 22, 
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or cleaved E-ring and 18,19-diketone system (Sarek et al., 2003). The group of Betulinines 
contains several compounds with significant antitumor activity against wide range of cancer 
cell lines, including MDR and melanoma lines (SK-MEL-2 MEL-3, B-16, B-16F), diketones 
118, and 119 and triketone 126 were among the best. Diketone 118, which is on the other 
tumor lines much more active than the acid 1, has shown activity in melanoma lines about 
three times worse than acid 1; Tab. 2, 4 (Sarek et al., 2003). Compounds with pyrazine and 
quinoxaline heterocycle condensed to the E-ring were not as active as compounds 118, 119, 
and 126 (Urban et al., 2007). Last but not least, we should mention quaternary ammonium 
salt 120 was the most active. 
Taraxastane derivatives - heterobetulinic acid (121) and heterobetulonic acid (122) should be 
formally included in this chapter. The acid 121 was firstly isolated from Calyptranthes pallens, 
(Lobo-Echeverri et al., 2005) but it is also available synthetically from betulin (3) in five steps 
(Bradbury & Mingjun, 2007), which include a rearrangement of lupane skeleton to 
taraxastane. Heterobetulinic acid (121) showed antitumor activity against melanoma lines 
M14 UACC62 and SK MEL 5 comparable to or slightly better than that of betulinic acid (1), 
Tab. 4. 
 
O
O
AcO
CO2R
118: R = CH3
119: R = Acm
AcO
CO2(CH2)2N
Br
O
120
R
CO2H
121: R = -OH,-H
122: R = O
 
Fig. 24. 
Des-E lupane derivatives 
Des-E lupane derivatives represent the ultimate synthetic step in the oxidative 
cleavage/degradation of the ring E of the 21,22-dioxolupane compounds using 
ruthenium(VIII) oxide. (Sarek et al., 2003) described several des-E-lupane compounds, most 
important are the -keto and -keto acids 123, 124 and methyleneketone 125. They are also 
named Betulinines. -Keto acid 124 (also called JS8) is the most promising anticancer drug 
within this group, based on the values of cytotoxic activity against more than 30 lines 
including MDR (the cytotoxicity was 1.28 mol/L for MEL-3, 4.3 mol/L for M14, and 1.16 
mol/L for SK-MEL-2; Tab. 4) (Sarek et al., 2003). It is essential to mention that, according to 
data from flow cytometry, JS8 causes selective apoptosis of tumor cells with rate comparable to 
the commercial cytostatic diterpenic drug paclitaxel. It was found that JS8 has a unique and 
new mechanism of action with primary target located in mitochondria. Compound JS8 is also 
very interesting from the chemical point of view, because it is a -keto acid that are known to 
be extremely unstable because they tend to decarboxylate spontaneously. Despite that, JS8 is 
relatively stable compound when stored at reduced temperature and it is probably due to a 
significant steric hindrance of the labile carboxyl group. As a tetracyclic pentanorlupane 
derivative, JS8 is very hydrophilic in comparison to the full-sized triterpenes, and so it is 
readily soluble in aqueous media (maximum solubility is 68 mg/mL) (Sarek et al., 2007). In 
conclusion, JS8 is highly antitumor compound, it has favorable solubility for the in vivo tests; 
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its structure, activity and manufacturing procedure has been patented (Fisher et al., 2003) and 
therefore it has a great chance to become an anticancer drug. Methyleneketone 125, one of the 
two degradation products of JS8, has similarly strong antitumor properties (activity against 
M14 was 4.3 mol/L and against SK-MEL 5 was 3.4 mol/L; Tab. 4) (Sarek et al., 2007). 
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Fig. 25. 
3. Conclusions and future directions 
Despite the fact that betulinic acid (1) was first isolated in 1902, it took another forty years to 
solve its structure and to identify that several compounds obtained from natural sources by 
other research groups were identical to it. Trumbull et al. was the first to discover the 
interesting cytotoxic activity of betulinic acid (1) in 1976 when he studied a chloroform extract 
of Vauquelinia corymbosa against lymphocytic leukemia cells anti-P-388. He suggested that 
uvaol, ursolic acid, and betulinic acid (1) are the components responsible for the cytotoxicity. 
After that, it took another 19 years until Pisha et al. confirmed that the activity is caused by 
betulinic acid (1) and these authors were first to report that the cytotoxicity is selective against 
human melanoma cells. This fact sparked intensive research and gave the oncologists hope for 
the birth of a new drug to combat the insidious disease with steadily increasing incidence. 
During early 90th of the last century, the scientists stood at the starting line – they had a 
natural substance with a quite complicated structure and available only in limited quantities 
from precious natural sources, however, the compound had strong and selective activity 
against melanoma and very low toxicity. The main disadvantage seemed to be its 
unfavorable pharmacokinetic parameters. After solving the difficulties with the availability 
of acid 1 by developing its synthetic procedure from betulin (3), the use of betulinic acid (1) 
was given a real dimension. As a result, several hundred semi-synthetic lupane analogues 
were published up today, derivatives of betulinic acid (1), pulsatillic acid (2), and betulin (3), 
many of those showed significant anticancer effects. They are more hydrophilic and their 
pharmacokinetic profile is improved. Some of them were tested in vitro on activity against 
human or murine melanoma cells and three of them were tested in vivo. 
There are several tens of derivatives with promising activity against melanoma cells in vitro; 
the most significant are artificially modified compounds as pulsatillates 24 - 29; NVX-207 
(30); conjugates of acid 1 with amino acids 33, 36, 37; quaternary ammonium salts 40, 41 and 
46 – 53, 85; some glycosides (the best showed to be: 32, 58, 59 and 64); hemiphtalates 72, 74; 
carbamate 54; compounds with modified isopropenyl chain (acid 90, 93, methoxyderivative 
92 and alcohol 91); compounds with modified A-ring (most active were compounds that 
have an EWG group in the location 2 of the 3-oxo lupane skeleton or the EWG with a 
multiple bond in conjugation with 3-oxo group – the best are 109 – 112, 114 and 117); 
compounds with modified E-ring where active was diketone 118 and heterobetulinic acid 
(121); and finally, the des-E-derivatives JS8 (124) and methyleneketone 125. 
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Betulinic acid (1) itself is now in phase II of clinical trials against dysplastic nevus, 
compound NVX-207 (30) was tested on dogs with particularly good results and pulsatillate 
24 was successfully tested on the mice models. These in vivo data together with current 
industrial availability of betulinic acid (1) and a variety of its active derivatives with 
improved hydrophilicity and a reasonable solubility in water-based media gives this group 
of natural compounds high potential to become a new generation of cytostatic drugs to 
combat a malignant melanoma. 
4. Tables of activities 
Compound B16 B16-F1 MEL-1 MEL-2 
1 53.5 16.1 6.3 1.3
2 83.0 ── ── ──
3 ── 13.8 ── ──
5 ── ── 31.8 0.1
13 ── 210.1 ── 244.1
14 ── ── ── 160.0
15 ── 26.0 ── ──
16 ── ── ── 217.9 
17 ── ── ── NA
24 80.5 ── ── ──
25 72.9 ── ── ──
26 80.9 ── ── ──
27 66.0 ── ── ──
28 41.1 ── ── ──
29 63.2 ── ── ──
30 ── ── ── ──
31 ── ── NA NA
33 ── ── ── 2.9
34 ── ── ── 4.1
35 ── ── ── 6.8
36 ── ── ── 8.0
37 ── ── ── 18.1
38 - - - 12.7
42 ── >248 ── ──
43 ── >228 ── ──
44 ── >175 ── ──
55 ── ── ── 247.0
56 ── ── ── 223.7
58 ── 7.1 ── ──
59 ── 3.9 ── ──
60 ── 11.0 ── ──
68 ── ── ── 3.4
69 ── ── ── 3.4
70 ── ── ── 4.2
71 ── ── ── 3.7
72 ── ── ── 13.4
73 ── ── ── 24.9
74 ── ── ── 90.0
75 - - - 1.5
77 ── ── ── 2.4
78 ── ── ── 8.3
79 ── ── ── 1.3
80 ── ── ── 2.2
81 ── ── ── NA  
Table 1. 
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Compound B16-F1 MEL-1 MEL-2 M14-MEL
91 - - 18.0 -
92 - - 20.0 -
93 - - 3.0 -
96 - NA NA -
97 - 14.1 14.1 -
98 - 21.5 33.3 -
99 - NA 0.5 -
100 - NA 0.4 -
102 - NA NA -
103 - - 23.0 -
109 2.7 - 1.5 -
110 3.0 - 0.21 -
111 0.55 - 0.50 -
112 6.1 - 31.2 -
114 3.1 - 2.2 -
116 - - 98.0 -
118 67.9 - 65.3 -
119 NA - NA -
123 11.5 - 19.9 -
124 0.4 - 1.2 4.3
125 0.7 - 2.1 -
126 34.3 - 223.7 -  
 
 
Table 2. 
 
 
Compound 518A2 Colo38 Bro WM3211 WM793
15 28.8 ── ── ── ──
30 2.6 ── ── ── ──
46 ── ── ── 0.6 2.5
47 ── ── ── 0.7 1.3
48 ── ── ── 0.3 1.9
49 ── ── ── 0.6 0.8
50 ── ── ── 0.3 0.5
51 ── ── ── 0.5 0.5
52 ── ── ── 0.4 0.4
53 ── ── ── 0.5 0.5
54 8.18 ── ── ── ──
82 17.8 ── ── ── ──
83 51.5 ── ── ── ──
84 16.7 ── ── ── ──
85 ── ── ── 2.6 5.7
87 ── 10 10 ── ──
88 ── > 10 > 10 ── ──  
 
 
Table 3. 
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Compound M14 UACC 62 SK MEL 5
1 5.4 5.0 4.5
38 16.7 22.3 4.7
41 14.6 1.6 2.2
64 21.1 19.0 18.4
75 12.7 12.6 9.3
90 9.2 5.8 6.9
104 54.0 29.8 27.6
116 41.2 14.7 6.3
118 15.8 14.7 11.3
121 6.2 4.6 3.5
122 45.8 13.9 6.4
124 4.9 3.5 3.8
125 4.3 3.5 3.4  
Table 4. 
Table 1-4: Table 1-3 - cytotoxicity (IC50 in µM) of published compounds against melanoma 
cell lines; Table 4 - cytotoxicity (IC50 in µM) selected semisynthetic lupane derivatives 
against melanoma cell lines which are part of the NCI60 cell lines panel and are therefore 
well characterized and further studied, e.g. cell line M14 is bearing the mutated p53 protein. 
NA is not active. 
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